Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Tumor-Agnostic 1Thoracic 1Other solid neoplasm 1Head & Neck 1Gynecologic 1

Conditions

Head and Neck Neoplasms 1

Interventions

Cisplatin 108Radiotherapy 45Docetaxel 44Radiotherapy, Intensity-Modulated 36Gemcitabine 31Fluorouracil 30camrelizumab 24toripalimab 21Drug Therapy 21Cetuximab 20apatinib 19Paclitaxel 16Carboplatin 16pembrolizumab 14Chemoradiotherapy 14Capecitabine 13Blood Specimen Collection 13sintilimab 12nimotuzumab 12Surveys and Questionnaires 10Surgical Procedures, Operative 10Endostatins 10Cyclophosphamide 9nedaplatin 8endostar protein 8durvalumab 8Nivolumab 8Neoadjuvant Therapy 8Induction Chemotherapy 8fludarabine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Megestrol Acetate × Head & Neck × Clear all
NCT02980653 2017-01-18

Megestrol Acetate Against Cancer-related Critical Body Weight Loss in Patients With H&N Cancer Who Receiving CCRT

TTY Biopharm

Phase 2 Unknown
105 enrolled
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡